Select Vaccines partner ships hep E kits to hotspot
Wednesday, 08 September, 2004
Select Vaccines' (ASX:SLT) licence partner Genelabs Diagnostics has provided the World Health Organisation with a "significant quantity" of the hepatitis E rapid diagnostic kits developed by Select, the company said today.
The kits, which were provided to the WHO on a humanitarian basis, will be used in the Darfur region of Sudan to help contain an outbreak of hepatitis E in the refugee camps. Select Vaccines licensed the hepatitis E rapid diagnostic kit, as well as a laboratory diagnostic to Genelabs for a 12-year term in August, in return for upfront payments and royalties.
Inhaled form of blood thinner treats serious COVID infections
Heparin has traditionally been injected and used to treat blood clots, but the new study tested...
Next-gen therapies could treat high-grade gliomas
Government funding will enable researchers to test a suite of next-generation therapies they have...
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
